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Aims The aim of this study was to compare early- and late-term survival and causes of death between patients with and
without a concomitant aortic valve (AoV) procedure during continuous-flow left ventricular assist device (LVAD)
surgery.
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Methods
and results
All adult primary continuous-flow LVAD patients on the International Society of Heart and Lung Transplantation
(ISHLT) Mechanically Assisted Circulatory Support (IMACS) Registry (n = 15 267) were included in this analysis and
stratified into patients submitted to a concomitant AoV procedure (AoV replacement or AoV repair) and patients
without an AoV procedure. The primary outcome was early (≤90 days) survival post-LVAD surgery. Secondary
outcomes were late survival (survival during the entire follow-up period) and conditional survival (in patients
who survived the first 90 days post-LVAD surgery), and determinants. Patients who underwent concomitant AoV
replacement (n = 457) had significantly reduced late survival compared with patients with AoV repair (n = 328)
or without an AoV procedure (n = 14 482) (56% vs. 61% and 62%, respectively; P = 0.001). After adjustment for
other significant predictors, concomitant AoV replacement remained an independent predictor for early [hazard ratio
(HR) 1.226, 95% confidence interval (CI) 1.037–1.449] and late (HR 1.477, 95% CI 1.154–1.890) mortality. However,
patients undergoing AoV replacement or repair, in whom the presence of moderate-to-severe AoV regurgitation was
diagnosed prior to LVAD implantation, had survival similar to patients not undergoing AoV interventions.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions Concomitant AoV surgery in patients undergoing LVAD implantation is an independent predictor of mortality.
Additional research is needed to determine the best AoV surgical strategy at the time of LVAD surgery.
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Introduction
In recent years, increasing numbers of patients have received a left
ventricular assist device (LVAD) as treatment for end-stage heart
failure (HF).1 However, significant aortic valve (AoV) regurgitation
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.. in patients with an LVAD causes a short circulation loop, in which
blood is pumped into the aorta by the LVAD and flows directly
back into the left ventricle.2 This results in less unloading of
the left ventricle and reduced systemic perfusion, indicated by
an increased left ventricular end-diastolic diameter and higher
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levels of brain natriuretic peptide.3 Additionally, significant AoV
regurgitation has been associated with increased mortality and
higher hospitalization rates.3,4 Therefore, the performance of a
concomitant AoV procedure in patients with moderate-to-severe
AoV regurgitation at the time of LVAD surgery is recommended.5
Additionally, a concomitant AoV procedure at the time of LVAD
surgery in patients with a mechanical AoV is also recommended5
because mechanical AoVs in LVAD patients are associated with
increased risk for thromboembolic events.6,7 The decision to
perform a concomitant AoV procedure can be based on additional
perioperative (transoesophageal) echocardiographic images.
Concomitant AoV replacement with a bioprosthetic valve, AoV
repair and the oversewing of the AoV are all considered as treat-
ment strategies, with associated risks and benefits.8 However, con-
flicting results on the outcomes of concomitant AoV procedures
have been reported and the contemporary data available on early
and late survival outcomes in concomitant AoV procedures are
limited.
The aim of this study was to compare early and late survival
and causes of early and late death in patients with and without
a concomitant AoV procedure during continuous-flow LVAD
surgery in the International Society of Heart and Lung Transplan-
tation (ISHLT) Mechanically Assisted Circulatory Support (IMACS)
Registry.
Methods
The IMACS Registry is a multinational, multicentre database that col-
lects prospective data and has been described previously.9 In short, the
aim of the IMACS Registry is to enrol and monitor patients implanted
with durable mechanical circulatory support devices, worldwide. The
registry receives data from the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS), the European Registry
for Patients with Mechanical Circulatory Support (EUROMACS), the
United Kingdom (UK) Registry and the Japanese Mechanically Assisted
Circulatory Support (JMACS) Registry, as well as from individual
hospitals worldwide.
All adult patients (aged ≥18 years) who underwent primary implan-
tation of a continuous-flow LVAD from January 2013 to November
2017 were included in this analysis. Patients with a total artificial heart,
isolated right ventricular assist device or with missing information on
concomitant AoV procedures were excluded from this analysis (Sup-
plementary material online, Figure S1). The endpoints for this anal-
ysis was all-cause mortality post-LVAD surgery, device explantation
and heart transplantation. The primary outcome was early (≤90 days
post-LVAD surgery) survival. Secondary outcomes were late (survival
during the entire follow-up period) and conditional survival (in patients
who survived the first 90 days post-LVAD surgery), causes of early and
late death post-LVAD surgery, device explantation and heart transplan-
tation. Causes of death were as defined earlier by the IMACS Registry
because granular data on the causes of death were not available.9
Statistical analysis
Patient characteristics are presented as the mean± standard deviation
or median and interquartile range (IQR), depending on the distribution
of continuous data, and as counts and percentages for categorical data.



















































































.. were used to compare data for continuous variables, depending on
the distribution of the data, and the chi-squared test was used to
compare data for categorical variables. All LVAD patients included were
stratified into those without a concomitant AoV procedure and those
with AoV intervention (replacement or concomitant AoV repair) at
LVAD implant. Additional data on which type of AoV repair technique
was used were not available.
The probability of survival was analysed using the Kaplan–Meier
method and compared using the log-rank test. A univariable Cox pro-
portional hazard analysis was used to relate preoperative parameters,
such as demographics, medication, echocardiographic, haemodynamic
and laboratory characteristics with the study outcomes (Supplemen-
tary material online, Tables S1 and S2). Variables with a P-value of <0.20
were entered in a multivariable Cox proportional hazard analysis in
order to adjust the prediction of AoV procedures for confounders,
applying the stepwise forward method, with a P-value of <0.05 as a
model-entry criterion. Data were censored at heart transplantation
or device explantation brought about by recovery. The competing out-
comes methodology was used to estimate the probabilities of survival,
mortality, heart transplantation or device explantation over time.
Several subanalyses were performed, including a survival analysis in
patients with documented moderate-to-severe AoV regurgitation, a
survival analysis stratified by INTERMACS class status, device destina-
tion and presence of AoV regurgitation, and a subanalysis excluding
patients who proceeded to heart transplantation.
Missing data in the baseline variables were imputed using multiple
imputation. If the missing variables showed a monotone pattern of
missing values, the monotone method was used; otherwise, an iterative
Markov chain Monte Carlo method was used with a number of 10
iterations. A total of five imputations were performed and the pooled
data were analysed. Variables with less than 40% missing data in the
entire population were accepted for multiple imputation.10 The vast
majority of variables had less than 5% missing data (Supplementary
material online, Table S3). The imputed data were used only in the Cox
proportional hazard analysis.
A two-tailed P-value of <0.05 was considered to indicate statistical
significance. All analyses were performed using IBM SPSS Statistics
Version 25.0 (IBM Corp., Armonk, NY, USA).
The findings herein were reviewed and approved by the IMACS
Steering Committee.
Results
In total, 15 267 LVAD patients were included in this analysis and
were stratified into those without an AoV procedure (n = 14 482,
94.9%), those undergoing AoV replacement (n = 457, 3.0%)
and those undergoing AoV repair (n = 328, 2.1%). The median
follow-up period was 13.2 months (IQR 5.5–25.6 months). The
baseline characteristics are summarized in Table 1. Overall, the
median patient age at LVAD surgery was 58 years, the major-
ity of patients were men (79.3%) and the main aetiology of HF
was non-ischaemic (61.5%). No AoV regurgitation prior to LVAD
surgery was reported in 67.2% of patients without an AoV proce-
dure, in 15.9% of patients with an AoV replacement and in 10.9%
of patients with an AoV repair (P < 0.001). Patients with an AoV
repair were significantly older compared with patients without an
AoV procedure or with AoV replacement (P < 0.001), had a lower
body mass index (P < 0.001), lower platelet count (P = 0.001), and
received an LVAD more often as destination therapy (P = 0.001).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Demographics
Age, years, median (IQR) 58.0 (49.0–66.0) 58.0 (48.0–66.0) 62.0 (53.0–69.0) 64.0 (57.0–69.0) <0.001
Men, n (%) 12 093 (79.3%) 11 433 (79.1%) 396 (87.0%) 264 (80.5%) <0.001
BSA, m2, median (IQR) 2.04 (1.85–2.25) 2.04 (1.86–2.25) 1.99 (1.83–2.18) 1.96 (1.81–2.16) <0.001
BMI, kg/m2, median (IQR) 27.4 (23.8–32.0) 27.5 (23.9–32.1) 26.1 (22.8–30.4) 25.1 (22.8–29.4) <0.001
Ischaemic aetiology, n (%) 5721 (38.5%) 5451 (38.6%) 147 (35.6%) 123 (39.5%) 0.437
Comorbidities, n (%)
CVA 655 (4.4%) 621 (4.4%) 21 (4.8%) 13 (4.1%) 0.877
DM 1477 (9.9%) 1417 (10.0%) 37 (8.3%) 23 (7.0%) 0.105
Current smoker 866 (5.9%) 818 (5.9%) 29 (6.9%) 19 (5.8%) 0.693
Dialysis 444 (2.9%) 423 (2.9%) 16 (3.5%) 5 (1.5%) 0.246
Current ICD therapy 10 392 (78.1%) 9860 (78.1%) 279 (76.9%) 253 (81.9%) 0.393
History of CABG 2544 (19.0%) 2415 (19.1%) 68 (17.8%) 61 (19.4%) 0.814
Atrial fibrillation 1408 (21.9%) 1309 (21.6%) 58 (28.6%) 41 (22.8%) 0.058
NYHA class, n (%)
I/II 174 (1.2%) 164 (1.2%) 7 (1.6%) 3 (1.0%) 0.761
III 2690 (19.2%) 2558 (19.3%) 79 (18.6%) 53 (17.0%)
IV 11 151 (79.6%) 10 557 (79.5%) 339 (79.8%) 255 (82.0%)
INTERMACS class, n (%)
1 2373 (15.6%) 2269 (15.8%) 60 (13.3%) 44 (13.4%) 0.502
2 5173 (34.1%) 4887 (34.0%) 165 (36.5%) 121 (36.9%)
3 5179 (34.1%) 4914 (34.1%) 156 (34.5%) 109 (33.2%)
4 1968 (13.0%) 1873 (13.0%) 55 (12.2%) 40 (12.2%)
5 315 (2.1%) 296 (2.1%) 9 (2.0%) 10 (3.0%)
6 95 (0.6%) 86 (0.6%) 6 (1.3%) 3 (0.9%)
7 68 (0.4%) 66 (0.5%) 1 (0.2%) 1 (0.3%)
IABP prior to LVAD surgery, n (%) 4302 (28.9%) 4109 (29.1%) 105 (24.0%) 88 (26.8%) 0.049
ECMO prior to LVAD surgery, n (%) 891 (6.0%) 853 (6.0%) 18 (4.1%) 20 (6.1%) 0.238
Ventilator prior to LVAD surgery, n (%) 1934 (12.7%) 1845 (12.8%) 48 (10.5%) 41 (12.5%) 0.364
History of AoV replacement/repair 396 (3.0%) 282 (2.2%) 85 (22.3%) 29 (9.2%) <0.001
Laboratory findings, median (IQR)
Creatinine, mg/dL 1.20 (0.98–1.50) 1.20 (0.97–1.50) 1.27 (1.05–1.57) 1.20 (1.00–1.50) 0.003
BUN, mg/dL 25.0 (18.0–37.3) 25.0 (18.0–37.0) 29.0 (21.0–40.0) 26.0 (18.0–36.0) <0.001
AST, U/L 29.0 (21.0–44.0) 29.0 (21.0–44.0) 30.0 (22.0–46.0) 30.0 (21.5–42.0) 0.226
ALT, U/L 29.0 (19.0–49.0) 29.0 (19.0–49.0) 28.5 (18.8–46.3) 29.0 (20.0–52.0) 0.782
LDH, U/L 279.0 (220.0–391.0) 279.0 (220.0–391.0) 289.5 (222.8–390.3) 276.5 (216.3–395.0) 0.753
Total bilirubin, mg/dL 1.0 (0.6–1.6) 1.0 (0.6–1.6) 1.1 (0.7–1.7) 1.1 (0.7–1.7) 0.010
WBC, ×109/L 7.9 (6.3–10.2) 7.9 (6.3–10.2) 7.8 (6.2–9.8) 7.5 (6.0–10.4) 0.167
Platelets, ×109/L 188.0 (142.0–242.0) 188.0 (142.0–242.0) 187.0 (132.0–232.0) 176.5 (131.3–226.0) 0.001
INR 1.2 (1.1–1.4) 1.2 (1.1–1.4) 1.3 (1.1–1.5) 1.2 (1.1–1.4) <0.001
Albumin, g/dL 3.5 (3.0–3.8) 3.5 (3.0–3.8) 3.4 (3.0–3.8) 3.4 (3.0–3.8) 0.552
Haemoglobin, g/dL 11.3 (9.8–12.8) 11.3 (9.8–12.8) 11.2 (9.9–12.6) 11.2 (9.7–12.5) 0.539
Haemodynamics, median (IQR)
RA pressure, mmHg 11.0 (7.0–16.0) 11.0 (7.0–16.0) 11.0 (7.0–17.0) 10.5 (7.0–15.0) 0.295
PCWP, mmHg 25.0 (19.0–31.0) 25.0 (19.0–31.0) 25.0 (20.0–31.0) 25.0 (19.0–32.0) 0.551
Systolic PAP, mmHg 50.0 (40.0–60.0) 50.0 (40.0–60.0) 51.0 (41.0–63.0) 50.0 (40.0–60.0) 0.012
Diastolic PAP, mmHg 25.0 (19.0–30.0) 25.0 (19.0–30.0) 25.0 (20.0–32.0) 24.0 (18.0–29.0) 0.026
Cardiac output, L/min 3.93 (3.14–4.80) 3.96 (3.15–4.80) 3.90 (3.20–4.71) 3.79 (3.00–4.55) 0.077
Echocardiographic data, n (%)
LVEF
≥40% 347 (8.5%) 327 (8.5%) 18 (14.4%) 2 (1.8%) 0.012
30–39% 484 (11.8%) 460 (11.9%) 12 (9.6%) 2 (10.7%)
20–29% 3260 (79.7%) 3067 (79.6%) 95 (76.0%) 98 (87.5%)
RVEF
Normal 2941 (26.0%) 2790 (26.1%) 73 (22.4%) 78 (28.4%) 0.400
Mild 3272 (29.0%) 3086 (28.9%) 108 (33.1%) 78 (28.4%)
Moderate 3473 (30.8%) 3283 (30.7%) 103 (31.6%) 87 (31.6%)
Severe 1606 (14.2%) 1532 (14.3%) 42 (12.9%) 32 (11.6%)
Mitral valve regurgitation
None 1070 (7.6%) 1021 (7.6%) 32 (7.7%) 17 (5.4%) 0.067
Mild 4960 (35.2%) 4689 (35.1%) 164 (39.7%) 107 (34.3%)
Moderate 4689 (33.3%) 4431 (33.2%) 138 (33.4%) 120 (38.5%)
Severe 3368 (23.9%) 3221 (24.1%) 79 (19.1%) 68 (21.8%)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Tricuspid valve regurgitation
None 1257 (9.0%) 1210 (9.1%) 31 (7.5%) 16 (5.1%) 0.172
Mild 6865 (49.2%) 6491 (49.1%) 207 (49.8%) 167 (53.4%)
Moderate 4197 (30.1%) 3969 (30.0%) 134 (32.2%) 94 (30.0%)
Severe 1640 (11.7%) 1560 (11.8%) 44 (10.6%) 36 (11.5%)
AoV regurgitation
None 8426 (64.4%) 8330 (67.2%) 63 (15.9%) 33 (10.9%) <0.001
Mild 4084 (31.2%) 3747 (30.2%) 182 (45.8%) 155 (51.3%)
Moderate 492 (3.8%) 270 (2.2%) 119 (30.0%) 103 (34.1%)
Severe 91 (0.7%) 47 (0.4%) 33 (8.3%) 11 (3.6%)
LVEDD, mm, median (IQR) 68.0 (61.0–75.0) 68.0 (61.0–75.0) 69.0 (63.0–77.0) 68.0 (62.0–74.0) 0.009
Main LVAD strategy, n (%)
BTT 4272 (28.0%) 4087 (28.2%) 116 (25.4%) 69 (21.0%) 0.001
BTC 4221 (27.7%) 4016 (27.7%) 126 (27.6%) 79 (24.1%)
Destination therapy 6563 (43.0%) 6177 (42.7%) 206 (45.1%) 180 (54.9%)
Rescue therapy 125 (0.8%) 122 (0.8%) 3 (0.7%) 0 (0%)
Bridge to recovery 55 (0.4%) 51 (0.4%) 4 (0.9%) 0 (0%)
Other 28 (0.2%) 26 (0.2%) 2 (0.4%) 0 (0%)
Concomitant procedures, n (%)
Congenital surgery 1030 (6.7%) 965 (6.7%) 39 (8.5%) 26 (7.9%) 0.201
Mitral valve surgery 538 (3.5%) 484 (3.3%) 26 (5.7%) 28 (8.5%) <0.001
Tricuspid valve surgery 533 (3.5%) 486 (3.4%) 26 (5.7%) 21 (6.4%) <0.001
Pulmonary valve surgery 8 (0.1%) 7 (0.007%) 1 (0.2%) 0 (0%) 0.268
RVAD surgery 99 (0.7%) 90 (0.7%) 8 (2.1%) 1 (0.3%) 0.005
Other concomitant surgery 2732 (17.9%) 2584 (17.8%) 85 (18.6%) 63 (19.2%) 0.754
ALT, alanine aminotransaminase; AoV, aortic valve; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; BTC, bridge to candidacy; BTT, bridge to transplant; BUN, blood urea
nitrogen; CABG, coronary artery bypass graft; CVA, cerebrovascular accident; DM, diabetes mellitus; ECMO, extracorporeal membrane oxygenator; IABP, intra-aortic balloon pump; ICD, implantable
cardioverter defibrillator; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; IQR, interquartile range; LDH, lactate dehydrogenase;
LVAD, left ventricular assist device; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCWP,
pulmonary capillary wedge pressure; RA, right atrial; RVAD, right ventricular assist device; RVEF, right ventricular ejection fraction; WBC, white blood count.
Patients who received an AoV replacement were more often men
(P < 0.001) and had a higher blood urea nitrogen level (P < 0.001)
compared with patients without an AoV procedure or with an AoV
repair. The baseline and clinical characteristics of 583 patients with
documented moderate-to-severe AoV regurgitation at baseline are
shown in Supplementary material online, Table S4.
Early, late and conditional survival
In the combined cohort of patients, the early survival rate
(≤90 days post-LVAD surgery) was 90.3%, the late survival rate
(up to 36 months post-LVAD surgery) was 62.1%, and the con-
ditional survival rate (up to 36 months post-LVAD surgery in
patients alive at 90 days post-LVAD surgery) was 68.8%. Early sur-
vival rates were 90.4% in patients without an AoV procedure,
85.1% in patients with an AoV replacement and 87.4% in patients
with an AoV repair (P < 0.001) (Figure 1A). Although late survival
rates differed significantly, at 62.4%, 55.5% and 60.9%, respectively
(P = 0.001) (Figure 1B), the largest difference occurred in early sur-
vival post-LVAD surgery. No additional difference was observed
in conditional survival rates (69.0%, 65.2% and 69.7%, respectively
(P = 0.268) (Supplementary material online, Figure S2).
Patients without an AoV procedure stayed in the intensive care
unit for a shorter period [median stay: 7 days (IQR 5–13 days)]
compared with patients with an AoV replacement [median stay:






































. stay: 8 days (IQR 5–14 days)] (P < 0.001). Similarly, patients without
an AoV procedure had a shorter hospital stay [median stay: 19 days
(IQR 14–28 days)] compared with patients with an AoV replace-
ment [median stay: 21 days (IQR 16–36 days)] and patients with
an AoV repair [median stay: 20 days (IQR 14–30 days)] (P < 0.001).
During the initial hospitalization, 843 (5.8%) patients without an
AoV procedure, 44 (9.6%) patients with an AoV replacement and
eight (2.4%) patients with an AoV repair died (P < 0.001).
The worst early and late survival rates were observed in patients
who underwent mechanical AoV replacement procedures (82.7%
and 50.6%, respectively), followed by those with biological AoV
replacements (85.6% and 56.4%, respectively), and those submitted
to AoV repair (87.4% and 60.9%, respectively), whereas patients
without an AoV procedure demonstrated the best early and
late survival rates (90.4% and 62.4%, respectively) (P < 0.001 and
P = 0.001, respectively) (Supplementary material online, Figure S3).
The baseline characteristics of patients in whom biological and
mechanical AoV replacements, AoV repair and no AoV procedure
were performed are shown in Supplementary material online,
Table S5.
Patients with an AoV procedure and an INTERMACS class of
2 or 3 had significantly worse survival compared with patients
without an AoV procedure, whereas no survival difference was
observed in patients with an INTERMACS class of 1 or 4 and
higher (Supplementary material online, Figure S4). Causes of death
are shown in Supplementary material online, Table S6.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 (A) Early and (B) late survival stratified according to
aortic valve (AoV) procedure post-left ventricular assist device
(LVAD) surgery.
Analyses of competing outcomes among the patient cohorts
demonstrated that patients with an AoV replacement (29.0%) and
patients with AoV repair (29.4%) less often underwent transplan-
tation at 36 months post-LVAD surgery compared with patients
without an AoV procedure (36.3%) (Supplementary material
online, Figure S5).
In patients who did not proceed towards heart transplanta-
tion, patients without an AoV procedure had the best survival
(Supplementary material online, Figure S6). No significant differ-
ence in early or medium-term survival was observed between
patients who received the LVAD as a bridge to transplantation or
as destination therapy, respectively (Supplementary material online,
Figure S7).
Survival in patients
with moderate-to-severe aortic valve
regurgitation
No significant differences in early, late or conditional survival rates
were observed among patients without an AoV procedure (89.4%,
58.5% and 65.4%, respectively), AoV replacement (90.6%, 57.5%
and 63.5%, respectively) or AoV repair (86.7%, 61.3% and 70.8%,
respectively) (Figure 2). Early, late and conditional survival rates in
patients without an AoV procedure, stratified by AoV regurgitation
at baseline, are shown in Supplementary material online, Figure S8.
Rates of late survival in patients without an AoV procedure, with




















































































Figure 2 (A) Early, (B) late and (C) conditional survival in
patients with moderate-to-severe aortic valve (AoV) regurgita-
tion at baseline, stratified by no AoV procedure, AoV replace-
ment and AoV repair post-left ventricular assist device (LVAD)
surgery.
AoV regurgitation at baseline, are shown in Supplementary material
online, Figure S9.
Causes of death
The causes of early and late death post-LVAD surgery are shown
in Table 2 and Supplementary material online, Table S7. Multisystem
organ failure was the most frequent cause of early death (27.7%),
followed by circulatory failure (16.9%) and neurological events
(15.9%). The most frequent cause of late death was neurological
events (19.2%), followed by multisystem organ failure (17.5%) and
circulatory failure (17.2%). The causes of death in patients surviving
the first 90 days post-LVAD surgery are shown in Supplementary
material online, Table S8.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Multisystem organ failure 402 (27.7%) 368 (27.4%) 22 (32.8%) 12 (29.3%)
Circulatory failure 246 (16.9%) 230 (17.1%) 7 (10.4%) 9 (22.0%)
Neurological events 231 (15.9%) 220 (16.4%) 7 (10.4%) 4 (9.8%)
Withdrawal of support 161 (11.1%) 150 (11.2%) 6 (9.0%) 5 (12.2%)
Major infection 110 (7.6%) 101 (7.5%) 4 (6.0%) 5 (12.2%)
RV failure 80 (5.5%) 76 (5.7%) 3 (4.5%) 1 (2.4%)
Respiratory failure 72 (5.0%) 66 (4.9%) 4 (6.0%) 2 (4.9%)
Digestive/liver failurea 21 (1.4%) 21 (1.6%) 0 (0%) 0 (0%)
Device-related 10 (0.7%) 9 (0.7%) 1 (1.5%) 0 (0%)
Haematologic failure 8 (0.6%) 7 (0.5%) 1 (1.5%) 0 (0%)
Cancer 1 (0.1%) 1 (0.1%) 0 (0%) 0 (0%)
Other 110 (7.6%) 95 (7.1%) 12 (17.9%) 3 (7.3%)
AoV, aortic valve; RV, right ventricular.
P-value for distribution between groups: 0.454.
aIncluding hepatic dysfunction, renal dysfunction, pancreatitis.
Multivariable model
Independent risk factors for early mortality post-LVAD surgery
after multivariable adjustment are shown in Table 3. Replacement
of the AoV was significantly associated with an increased risk for
early all-cause mortality, both unadjusted [hazard ratio (HR) 1.604,
95% confidence interval (CI) 1.255–2.05; P < 0.001] and adjusted
(HR 1.477, 95% CI 1.154–1.890; P = 0.002) for other significant
predictors, whereas AoV repair was not a significant predictor
compared with no AoV procedure. Similarly, AoV replacement was
a predictor for late all-cause mortality, both unadjusted (HR 1.360,
95% CI 1.152–1.605; P < 0.001) and adjusted (HR 1.226, 95% CI
1.037–1.449; P = 0.017) for other significant predictors (Table 4).
Discussion
This is the largest contemporary study to investigate outcomes
after continuous-flow LVAD implantation with and without a con-
comitant AoV procedure. The main findings of this study refer to
decreased survival, particularly early survival, in patients submitted
to AoV replacement compared with patients without an AoV pro-
cedure, especially in patients with less than moderate-to-severe
preoperative AoV regurgitation. Following adjustment for other
significant predictors, AoV replacement remained an independent
predictor for all-cause mortality. Furthermore, the main causes of
early death included multiorgan failure, circulatory failure and neu-
rological events.
Untreated significant AoV regurgitation can be very haemody-
namically compromising as a result of the short circulation loop,
whereas less severe AoV regurgitation may be less cumbersome.
Surprisingly, in up to 15% of the present patients who underwent
an AoV procedure, no AoV regurgitation was reported prior to
LVAD surgery. In these patients, the decision to perform an AoV
procedure may have been based on findings of significant AoV


















































.. echocardiogram. Additionally, these patients may have undergone
a concomitant AoV procedure in order to replace or over-
sew the AoV in the context of a pre-existing mechanical AoV,
as is recommended.5 However, neither perioperative echocar-
diographic data nor data on the replacement of a mechanical
AoV were collected in the IMACS database and therefore these
hypotheses could not be tested. However, the present results
indicate that AoV replacement is an independent predictor for
mortality. In patients with preoperative moderate-to-severe AoV
regurgitation, similar survival rates were observed in patients with
and without a concomitant AoV procedure. These results suggest
that patients with only mild preoperative AoV regurgitation who
underwent concomitant AoV replacement had worse survival than
patients without concomitant AoV replacement. These findings
indicate that stringent criteria for a concomitant AoV procedure at
the time of LVAD surgery may be warranted, especially in patients
with only mild AoV regurgitation. Concomitant AoV procedures
should be considered in patients with moderate-to-severe AoV
regurgitation in view of the significant impact on effective LVAD
circulation and potential risk for HF relapse or arrhythmias in
long-term patient management.3,4 Additionally, less invasive proce-
dures for the treatment of significant AoV regurgitation in LVAD
patients have been suggested. The use of a transcatheter aortic
valve replacement (TAVR) procedure to treat significant AoV
regurgitation in patients already on LVAD support has been inves-
tigated in small studies, which have shown promising results.11–13
The concomitant use of a TAVR procedure with LVAD surgery
could reduce circulatory bypass time, thereby reducing the risk
for myocardial ischaemia, as shown in a recent case report.14
However, both experience with and evidence for this off-label
use of the TAVR procedure are very limited, and this technique
may have additional limitations with reference to the challenges
associated with performing procedures of this type in LVAD
patients. Additional trials to determine the optimal strategy for
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Multivariable predictors of early all-cause mortality in post-left ventricular assist device surgery patients
stratified by aortic valve procedure
Variable HR 95% CI for HR P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lower Upper
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable No AoV procedure Ref Ref Ref Ref
AoV replacement 1.604 1.255 2.050 <0.001
AoV repair 1.331 0.976 1.816 0.071
Multivariable No AoV procedure Ref Ref Ref Ref
AoV replacement 1.477 1.154 1.890 0.002
AoV repair 1.209 0.885 1.652 0.233
Age 1.030 1.025 1.035 <0.001
Sex (men vs. women) 0.817 0.718 0.930 0.002
BMI 1.019 1.011 1.028 <0.001
Creatinine 1.148 0.990 1.333 0.068
BUN 1.007 1.005 1.010 <0.001
AST 1.000 1.000 1.001 0.003
Total bilirubin 1.197 1.127 1.272 <0.001
Platelet 0.999 0.998 1.000 0.001
Albumin 0.728 0.663 0.800 <0.001
Haemoglobin 0.924 0.898 0.951 <0.001
Mean RA pressure 1.011 1.004 1.019 0.004
Pulmonary artery wedge pressure 0.990 0.983 0.996 0.002
Moderate/severe tricuspid regurgitation 1.285 1.148 1.438 <0.001
Moderate/severe mitral regurgitation 0.796 0.712 0.889 <0.001
ECMO 1.612 1.345 1.932 <0.001
LVAD strategy
BTT Ref Ref Ref Ref
BTC 0.936 0.802 1.093 0.402
DT 1.109 0.966 1.274 0.143
Rescue therapy 2.233 1.147 4.347 0.018
Bridge to recovery 2.527 1.781 3.585 <0.001
Other 1.325 0.423 4.152 0.629
AoV, aortic valve; AST, aspartate transaminase; BMI, body mass index; BTC, bridge to candidacy; BTT, bridge to transplant; BUN, blood urea nitrogen; CI, confidence interval;
DT, destination therapy; ECMO, extracorporeal membrane oxygenator; HR, hazard ratio; LVAD, left ventricular assist device; RA, right atrial.
the treatment of significant AoV regurgitation at the time of LVAD
surgery are very much needed. The present results demonstrate
that in patients with significant AoV regurgitation, survival rates
are lower than in other patients undergoing LVAD implantation
and are not influenced by concomitant AoV surgery.
Early and late survival
Previous studies investigating the association between survival
and AoV procedures reported conflicting results, with some
studies indicating worse survival,15–18 whereas others reported
similar or better survival rates in patients with a concomitant
AoV procedure.19–23 However, most of these reports referred
to single-centre studies and were limited by lower numbers of
patients undergoing a concomitant AoV procedure (only one study
included more than 100 patients with an AoV procedure), and
some reported only outcomes of multiple concomitant cardiac
procedures combined. The largest study used the INTERMACS
dataset and included 6721 adult LVAD patients, of whom 125




























.. and 85 underwent AoV replacement between June 2006 and
December 2012.15 In the INTERMACS study, patients undergoing
a concomitant AoV procedure had significantly lower 1-year sur-
vival rates (79% in patients undergoing AoV repair, 72% in patients
undergoing AoV replacement and 64% in patients undergoing AoV
closure) compared with patients without an AoV procedure (81%)
(P = 0.0003). In comparison with the INTERMACS study,15 the
current study reflects a more contemporary worldwide LVAD pop-
ulation and includes a much higher number of LVAD patients and
a higher number of AoV procedures. The late survival rates in the
present study were higher than in the INTERMACS study, which
most probably reflects improvements in LVAD management and
survival that have occurred over time. Similarly to the INTERMACS
study,15 the present results demonstrate a lower survival rate in
patients with an AoV procedure, although the lowest survival rates
were recorded in patients with an AoV replacement in this study
but in patients with an AoV closure in the INTERMACS study.
Only biological prostheses are recommended for concomitant
AoV replacement, and a concomitant AoV procedure at the time
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Multivariable predictors of late all-cause mortality in post-left ventricular assist device surgery patients
stratified by aortic valve procedure
Variable HR 95% CI for HR P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lower Upper
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable No AoV procedure Ref Ref Ref Ref
AoV replacement 1.360 1.152 1.605 <0.001
AoV repair 1.150 0.933 1.418 0.190
Multivariable No AoV procedure Ref Ref Ref Ref
AoV replacement 1.226 1.037 1.449 0.017
AoV repair 1.052 0.853 1.298 0.635
Age 1.024 1.021 1.028 <0.001
BMI 1.016 1.011 1.022 <0.001
Ischaemic aetiology 1.070 1.001 1.144 0.047
INTERMACS class (1–3 vs. 4–7) 1.101 1.005 1.207 0.040
Creatinine 1.111 1.014 1.217 0.024
BUN 1.006 1.004 1.007 <0.001
Total bilirubin 1.085 1.042 1.129 <0.001
Platelet 0.999 0.999 1.000 0.016
INR 1.062 0.995 1.134 0.070
Albumin 0.872 0.822 0.924 <0.001
Haemoglobin 0.938 0.922 0.954 <0.001
Mean RA pressure 1.011 1.006 1.015 <0.001
PAWP 0.992 0.988 0.996 <0.001
Moderate/severe tricuspid regurgitation 1.144 1.068 1.226 <0.001
Moderate/severe mitral regurgitation 0.845 0.790 0.904 <0.001
IABP 1.074 1.000 1.154 0.050
ECMO 1.354 1.185 1.546 <0.001
LVAD strategy
BTT Ref Ref Ref Ref
BTC 0.979 0.889 1.077 0.661
DT 1.145 1.050 1.248 0.002
Rescue therapy 1.484 0.873 2.521 0.145
Bridge to recovery 1.599 1.201 2.128 0.001
Other 0.806 0.301 2.159 0.668
AoV, aortic valve; BMI, body mass index; BTC, bridge to candidacy; BTT, bridge to transplant; BUN, blood urea nitrogen; CI, confidence interval; DT, destination therapy;
ECMO, extra-corporeal membrane oxygenator; HR, hazard ratio; IABP, intra-aortic balloon pump; INR, international normalized ratio; INTERMACS, Interagency Registry for
Mechanical Assisted Circulatory Support; LVAD, left ventricular assist device; PAWP, pulmonary artery wedge pressure; RA, right atrial.
of LVAD surgery is recommended in patients with a mechanical
AoV.5 Despite these recommendations, a small number of patients
still received a concomitant mechanical AoV during LVAD surgery.
The present results clearly demonstrate that patients with a
mechanical AoV have the worst survival and thereby support
recommendations for the use of only biological prostheses in LVAD
patients.
Multiple closure and repair techniques, each with their own risks
and benefits, have been reported in LVAD patients.8 Variations
in the operating techniques used may explain the variations in
outcome after AoV repair observed between the INTERMACS
and IMACS studies. However, this hypothesis could not be tested
because neither database includes sufficient data to discriminate
between different operating techniques. Additionally, the present
results do not discriminate between AoV repair and closure,
which may contribute to the observed variation. However, in

























. from the heart is not possible, especially during catastrophic pump
dysfunction. Catastrophic pump dysfunction, although rare, is a
severe complication and represents the cause of death in 2% of
all LVAD patients.1 Additionally, oversewing of the AoV creates a
blind pouch, which potentially increases the risk for thrombus for-
mation on the AoV and hence raises the risk for thromboembolic
events. Therefore, the decision to close the AoV should not be
taken lightly.
Causes of death
In the present combined cohort of LVAD patients, the most com-
mon causes of early death were multisystem organ failure, circu-
latory failure and neurological events post-LVAD surgery, which
reflect the findings of a previous report.24 The lower survival
in patients with an AoV replacement appears to be accompa-
nied by an increase in multisystem organ failure, whereas patients
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undergoing AoV repair more often died as a result of circulatory
failure compared with patients without an AoV procedure. Surpris-
ingly, fatal neurological events occurred frequently, and more often
in patients without an AoV procedure, compared with patients
with a concomitant AoV replacement or repair. It is possible that
antithrombotic and antiplatelet therapy was introduced earlier in
patients submitted to an AoV procedure compared with patients
without an AoV procedure, and thereby prevented fatal neuro-
logical events. However, detailed information on the timing of the
introduction of antithrombotic and antiplatelet therapy was lack-
ing. Unfortunately, no granular data for more specification of the
causes of early and late death were available in the IMACS database.
The most common causes of late death were neurological
events, multiorgan failure and circulatory failure, which is in line
with previous reports from the INTERMACS, EUROMACS and
IMACS databases.1,24,25 Patients with an AoV replacement or
repair died more often as a result of multisystem organ failure, and
patients with an AoV repair died more often as a result of circu-
latory failure compared with patients without an AoV procedure.
Competing outcomes
In this cohort, LVAD patients with an AoV procedure were less
often submitted to transplant in comparison with patients without
an AoV procedure. As previously suggested, AoV regurgitation may
be treated more aggressively in patients with an LVAD as destina-
tion therapy.15 However, the observed difference between those
without an AoV procedure and those with AoV replacement is
not fully explained by the difference in device strategy. Potentially,
the significantly higher age of patients with an AoV replacement
may have influenced the decision not to proceed towards trans-
plantation after LVAD implantation.
Limitations
This study has some limitations. Firstly, as a result of its retrospec-
tive nature, this study lacks some data. Although multiple imputa-
tion was used to deal with the issue of missing data, this may have
caused a minor bias. Additionally, some errors may have occurred
during data entry. Secondly, in order to ensure data anonymization,
LVAD brand information is not available in the research database.
Therefore, brand-specific subanalyses could not be performed.
Data on the presence and severity of AoV regurgitation were avail-
able for all patients; however, information on why surgeons elected
to perform AoV replacement or repair, respectively, was not avail-
able. It is likely that such decisions varied among participating cen-
tres based on local experiences and preferences. Additionally, the
degree of AoV regurgitation was graded by the local site and not
by an independent core laboratory, and this may have caused some
bias. Lastly, no discrimination between AoV repair and closure was
made in the database.
Conclusions
This is the largest study to compare short- and long-term sur-



















































































.. LVAD patients with pre-existing AoV regurgitation. Concomitant
AoV surgery is associated with lower survival rates compared with
the absence of an AoV procedure. Particularly in patients with
only mild preoperative AoV regurgitation, survival rates are neg-
atively impacted by concomitant AoV replacement. These results
suggest that the resolution of mild AoV regurgitation may not out-
weigh the risks associated with AoV surgery, whereas the resolu-
tion of moderate-to-severe AoV regurgitation may improve LVAD
management. Therefore, additional research is urgently needed to
determine the optimal strategy for the treatment of AoV regurgi-
tation at the time of LVAD surgery.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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